Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SYS6002 versus investigator's choice chemotherapy in recurrent or metastatic cervical cancer after platinum chemotherapy and PD-1/L1 inhibitor failure
CTR20254536Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CRB-701 in Cervical Cancer (CC) (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Dec 2025; status: active.
02
Drugs
CRB-701
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20254536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254536.